表紙
市場調查報告書

藥物分析:Keytruda

Keytruda

出版商 Datamonitor Healthcare 商品編碼 603932
出版日期 內容資訊 英文 141 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物分析:Keytruda Keytruda
出版日期: 2019年09月09日內容資訊: 英文 141 Pages
簡介

本報告提供人體化單株抗體Keytruda的相關調查,主要國家/地區的銷售額成果與預測,各疾病的藥物評估、SWOT分析,及藥物簡介等。

  • 產品簡介
  • Keytruda:大腸癌 (CRC)
  • Keytruda:頭頸癌
  • Keytruda:肝癌 (HCC)
  • Keytruda:膀胱癌
  • Keytruda:腎細胞癌 (RCC)
  • Keytruda:非小細胞肺癌 (NSCLC)
  • Keytruda:瀰漫性大細胞型B細胞淋巴瘤 (DLBCL)
  • Keytruda:胃癌
  • Keytruda:乳癌 (三陰性)
  • Keytruda:黑色素瘤
  • Keytruda:多發性骨髓瘤

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0128795

Drug Overview:

Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses. It has also been hypothesized that blocking the PD-1/PD-L1 interaction may preferentially release the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Keytruda: Hepatocellular carcinoma (HCC)
    • Keytruda: Renal cell carcinoma (RCC)
    • Keytruda: NHL: Diffuse large B-cell lymphoma (DLBCL)
    • Keytruda: Non-small cell lung cancer (NSCLC)
    • Keytruda: Melanoma
    • Keytruda: Gastric cancer
    • Keytruda: Colorectal cancer (CRC)
    • Keytruda: Head and neck cancer
    • Keytruda: Bladder cancer
    • Keytruda: Breast cancer: triple-negative

LIST OF FIGURES

  • Figure 1: Datamonitor Healthcare's drug assessment summary of Keytruda for HCC
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Keytruda for HCC
  • Figure 3: Keytruda sales for HCC across the US, Japan, and five major EU markets, by country, 2018-27
  • Figure 4: Keytruda for RCC - SWOT analysis
  • Figure 5: Datamonitor Healthcare's drug assessment summary of Keytruda for RCC
  • Figure 6: Datamonitor Healthcare's drug assessment summary of Keytruda for RCC
  • Figure 7: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 8: Keytruda for diffuse large B-cell lymphoma - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
  • Figure 10: Datamonitor Healthcare's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
  • Figure 11: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 12: Keytruda for non-small cell lung cancer - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
  • Figure 14: Datamonitor Healthcare's drug assessment summary for Keytruda in non-small cell lung cancer
  • Figure 15: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 16: Keytruda in melanoma - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Keytruda for melanoma
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Keytruda for melanoma
  • Figure 19: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 20: Keytruda for gastric cancer - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Keytruda for gastric cancer
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Keytruda for gastric cancer
  • Figure 23: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 24: Keytruda for colorectal cancer - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Keytruda in colorectal cancer
  • Figure 27: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 28: Keytruda for head and neck cancer - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Keytruda for SCCHN
  • Figure 31: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 32: Keytruda for urothelial bladder cancer - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary for Keytruda in urothelial bladder cancer
  • Figure 34: Datamonitor Healthcare's drug assessment summary for Keytruda in urothelial bladder cancer
  • Figure 35: Keytruda for triple-negative breast cancer - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary of Keytruda for triple-negative breast cancer
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Keytruda for triple-negative breast cancer

LIST OF TABLES

  • Table 1: Recent high-impact events for Keytruda in HCC
  • Table 2: Keytruda drug profile
  • Table 3: Approval history of Keytruda for HCC in the US, Japan, and five major EU markets
  • Table 4: Trials of Keytruda for HCC
  • Table 5: Keytruda for HCC - SWOT analysis
  • Table 6: Keytruda drug profile
  • Table 7: Keytruda Phase III data in RCC
  • Table 8: Keytruda Phase III trials in RCC
  • Table 9: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 10: Keytruda drug profile
  • Table 11: Keytruda pivotal trial data in diffuse large B-cell lymphoma
  • Table 12: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 13: Keytruda drug profile
  • Table 14: Keytruda pivotal trial data in non-small cell lung cancer
  • Table 15: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
  • Table 16: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 17: Keytruda patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 18: Keytruda drug profile
  • Table 19: Keytruda pivotal trial data in melanoma
  • Table 20: Keytruda ongoing clinical trials in melanoma
  • Table 21: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 22: Keytruda patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 23: Keytruda drug profile
  • Table 24: Keytruda pivotal trial data in gastric cancer
  • Table 25: Keytruda Phase III trials in gastric cancer
  • Table 26: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 27: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 28: Keytruda drug profile
  • Table 29: Keytruda Phase III trial in colorectal cancer
  • Table 30: Keytruda early-phase data in colorectal cancer
  • Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016-25
  • Table 33: Keytruda drug profile
  • Table 34: Keytruda pivotal trial data in head and neck cancer
  • Table 35: Keytruda ongoing late-phase trials in head and neck cancer
  • Table 36: Keytruda early-phase data in head and neck cancer
  • Table 37: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 38: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 39: Keytruda drug profile
  • Table 40: Keytruda pivotal trial data in urothelial bladder cancer
  • Table 41: Keytruda ongoing late-phase trials in urothelial bladder cancer
  • Table 42: Keytruda early-phase data in urothelial bladder cancer
  • Table 43: Keytruda drug profile
  • Table 44: Keytruda Phase III trial in triple-negative breast cancer
  • Table 45: Keytruda Phase Ib data in triple-negative breast cancer
Back to Top